Clinical forms and evolution of hepatitis C;Formes cliniques et evolution de l'hepatite C

Revue du Praticien

Volumn 50, Issue 10, 2000, Pages 1083-1088

  Pol, Stanislas ^a   Zylberberg, Hervé ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; ARTICLE; BLOOD TRANSFUSION; DISEASE COURSE; DRUG EFFECT; FRANCE; HEPATITIS B VIRUS; HEPATITIS C; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INTRAVENOUS DRUG ABUSE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; REMISSION; SUPERINFECTION; ADULT; AGE; ALCOHOLISM; BIOPSY; CLASSIFICATION; DISEASE TRANSMISSION; FORECASTING; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOLOGY; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; TIME; VIROLOGY;

ANTIVIRUS AGENT;

ADULT; AGE FACTORS; ALCOHOLISM; ANTIVIRAL AGENTS; BIOPSY; FORECASTING; FRANCE; HEPATITIS B; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LIVER CIRRHOSIS; ORGAN TRANSPLANTATION; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 0034658017     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. .Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C infection in the United States, 1988 through 1994. N Engl J Med 1999 ; 341 : 556-62.
2. Dubois F, Désenclos JC, Mariotte N, Goudeau A and the collaborative study group. Hepatitis C in French population-based survey: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997 : 25 : 1490-96.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 ; 340 : 745-50.
4. Zylberberg H, Thiers V, Lagorce D et al. Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut 1999 ; 45 : 112-6.
5. Ohio H, Terazawa S, Sasaki N et al. Transmission of hepatitis C virus from mother to infants. N Engl J Med 1994 ; 330 : 744-50.
6. Liang TJ, Jeffers L, Reddy RK et al. Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses. Gastroenterology 1993 ; 104 : 556-62.
7. Seef LB. Natural history of hepatitis C. Hepatology 1997 ; 26 : 21S-28S.
8. Ivarson S, Norkrans G, Wejstal R. Hepatitis C: natural history of a unique infection. Clin Infect Dis 1995 ; 20 : 1364-70.
9. Yokosuka O, Kojima H, Imazeki F et al. Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years. J Hepatol 1999 ; 31 : 394-9.
10. Puoti C, Magrini A, Stati T et al Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997 ; 26 : 1393-8.
11. Koretz FL, Abbey H, Coleman E, Gitnick G. NonA-NonB post transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993 ; 119 : 110-5.
12. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder J, Alter HJ. Long term clinical and histopathological follow up of chronic post transfusion hepatitis. Hepatology 1991 ; 14 : 969-74.
13. Datz C, Cramp M, Haas T et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non A, non B hepatitis in a plasmapheresis centre. Gut 1999; 44 : 563-7.
14. Serfaty L, Aumaitre H, Chazouillieres O et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998 ; 27 : 1435-40.
15. Hu KQ, Myron JT. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999 ; 29 : 1311-6.
16. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 ; 349 : 825-32.
17. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D, and the study group for the prevalence and the epidemiology of hepatitis C virus. Hepatology 1997 ; 26 : 485-90.
18. Pol S, Fontaine H, Carnot F et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998 ; 29 : 12-9.
19. Silini E, Bottelli R, Asti M et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis : a case-control study. Gastroenterology 1996 ; 111 : 199-205.
20. Féray C, Gigou M, Samuel D et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995 ; 108 : 1088-96.
21. Zylberberg H, Carnot F, Mamzer MF, Blancho G, Pol S. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1997 ; 63 : 158-60.
22. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish hepatology Group. N Engl J Med 1999 ; 22 : 1228-33.
23. Tsukuma H, Himaya T, Taraka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993 ; 24 : 1797-801.
24. International interferon-alpha hepatocellular carcinoma study group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998 ; 351 : 1535-9.
25. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990 ; 12: 671-5.
26. Seeff LB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion associated non-A, non-B hepatitis.The national heart, lung, and blood institute study group. N Engl J Med 1992 ; 327 : 1906-11.
27. Darby SC, Ewart DW, Giangrande PLF et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997 ; 350 : 1425-31.
28. Legendre C, Garrigue V, Le Bihan C et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998 ; 65 : 667-70.
29. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996 ; 23 : 1117-25.
30. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997 ; 26 : 1-5.
31. Arribas JR, Ibanez C, Ruiz-Antoran B et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998 ; 12 : 1722-4.
32. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 1999 ; 31 : 369-76.
33. Cacoub P, Lunel-Fabiani F, Musset L et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1996 ; 36 : 124-32.
34. Garcia-Monzon C, Jara P, Fernandez-Bermejo M et al Chronic hepatitis in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology 1998 ; 28 : 1696-701.
35. Poynard T, Marcellin P, Lee SS et al. Randomised trial of Interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 ; 352 : 1426-32.